



## Proteon Therapeutics to Present at Two Upcoming Investor Conferences

August 29, 2018

WALTHAM, Mass., Aug. 29, 2018 (GLOBE NEWSWIRE) -- [Proteon Therapeutics, Inc.](http://www.proteontx.com) (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that Company management will present a corporate overview at the following upcoming investor conferences:

- The 20<sup>th</sup> Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, on September 5, 2018 in New York, NY; and
- The Baird 2018 Global Healthcare Conference on September 5, 2018 in New York, NY.

### About Proteon Therapeutics

Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon's lead product candidate, vonapanitase, is an investigational drug intended to improve hemodialysis vascular access outcomes. Proteon has completed enrollment in PATENCY-2, a Phase 3 clinical trial evaluating vonapanitase in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula for hemodialysis. Proteon is also evaluating vonapanitase in a Phase 1 clinical trial in patients with peripheral artery disease (PAD). For more information, please visit [www.proteontx.com](http://www.proteontx.com).

### Investor Contact

George Eldridge, Proteon Therapeutics, Senior Vice President and Chief Financial Officer  
781-890-0102  
[geldridge@proteontherapeutics.com](mailto:geldridge@proteontherapeutics.com)

### Media Contact

Ann Stanesa, Ten Bridge Communications  
617-230-0347  
[proteon@tenbridgecommunications.com](mailto:proteon@tenbridgecommunications.com)

 [Primary Logo](#)

Source: Proteon Therapeutics, Inc.